Semaglutide for the Treatment of Obesity in Children 6 to <12 Years of Age
Authors: Jastreboff, Ania M; Harder-Lauridsen, Nina M; Van Name, Michelle; Korner, Antje; Kelly, Aaron S; Weghuber, Daniel; Holm, Jens-Christian; Frithioff-Bojsoe, Christine; Middolu, Shilpa; Buch, Tina; Wabitsch, Martin
Source journal: The New England journal of medicine (2026-11-16)
Abstract
BACKGROUND: Childhood obesity is a chronic, neurometabolic disease with limited options for medical treatments that are efficacious and durable. Once-weekly subcutaneous semaglutide is approved for the treatment of obesity in adolescents and adults, but data for its use in young children are lacking. METHODS: We conducted a phase 3, double-blind, randomized, placebo-controlled trial involving children (6 to <12 years of age) with obesity. Participants were randomly assigned in a 2:1 ratio to receive once-weekly subcutaneous semaglutide or placebo for a period of 104 weeks, after which participants stopped taking semaglutide or placebo for a 7-week washout period. Both groups received counseling for lifestyle modification. The primary end point was the percent change in the body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) from baseline to week 68. The confirmatory secondary end point was a reduction in BMI category at week 68. RESULTS: Among 167 children who underwent randomization, 112 were assigned to receive semaglutide and 55 to receive placebo. At week 68, the mean percent change in BMI was -13.5% with semaglutide and 2.7% with placebo (estimated between-group difference, -16.2 percentage points; 95% confidence interval [CI], -19.4 to -12.9; P<0.001). The percent change in BMI at week 104 was -9.4% with semaglutide and 8.4% with placebo (between-group difference, -17.8 percentage points; 95% CI, -22.2 to -13.3). At week 68, a reduction in BMI category had occurred in 79% of the participants in the semaglutide group and in 23% of those in the placebo group (odds ratio, 7.8; 95% CI, 3.5 to 17.6; P<0.001), with the BMI below the threshold for obesity (the 95th percentile for age and sex) in 38% of the participants who received semaglutide and in 2% of those who received placebo. Adverse events occurred in 96% of the participants receiving semaglutide and in 93% of those receiving placebo. Gastrointestinal adverse events were the most common, occurred more frequently with semaglutide than with placebo, and led to discontinuation in 1 participant in the semaglutide group. CONCLUSIONS: Among children (6 to <12 years of age) with obesity, treatment with semaglutide for 68 weeks resulted in a significantly greater mean percent reduction in BMI than placebo. (Funded by Novo Nordisk; STEP Young ClinicalTrials.gov number, NCT05726227.).
Related topics
Related open access articles
- SCOBY papaya beverages induce gut microbiome interaction as potential antiobesity in weight management control supplement
- Milk Cereal Drink Feeding Practices: A Descriptive Study Among Swedish Children participating in the IDEFICS. Family Study
- Diet quality and body mass indices show opposite associations with distal gut microbiota in a low-income cohort
- ASSOCIATION BETWEEN SNACK ENERGY INTAKE IN CHILDREN AGED 8-11 AND MATERNAL BODY MASS INDEX: RESULTS FROM AN OBSERVATIONAL STUDY IN AN ELEMENTARY SCHOOL OF MILAN
- Murine model of obesity-induced type II diabetes by GADD34 (PPP1R15A) and other phosphatase 1 regulatory subunits deficiency.
- Studying the Influence of Storage Conditions, 1-MCP, and Packaging Films on Quality of Sweet Dalilah Green and Red Stage Peppers (Capsicum annuum L.)
Abstract and bibliographic data from PubMed (U.S. National Library of Medicine). Copyright of the abstract belongs to the original publisher or authors.